scholarly journals Simultaneous Measurement of Thyroxine and Thyrotropin from Newborn Dried Blood-Spot Specimens Using a Multiplexed Fluorescent Microsphere Immunoassay

2000 ◽  
Vol 46 (9) ◽  
pp. 1422-1424 ◽  
Author(s):  
Ronald Bellisario ◽  
Robert J Colinas ◽  
Kenneth A Pass
Keyword(s):  
Simultaneous Measurement ◽  
Dried Blood Spot ◽  
Fluorescent Microsphere ◽  
Blood Spot ◽  
Multiplexed Fluorescent Microsphere Immunoassay ◽  
Microsphere Immunoassay

scholarly journals Evaluation of Multiplexed Fluorescent Microsphere Immunoassay for Detection of Autoantibodies to Nuclear Antigens

2004 ◽  
Vol 11 (6) ◽  
pp. 1054-1059 ◽  
Author(s):  
Thomas B. Martins ◽  
Rufus Burlingame ◽  
Carlos A. von Mühlen ◽  
Troy D. Jaskowski ◽  
Christine M. Litwin ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Vascular Diseases ◽  
Disease Diagnosis ◽  
Specific Method ◽  
Serum Samples ◽  
Collagen Vascular Diseases ◽  
Fluorescent Microsphere ◽  
Nuclear Antigens ◽  
Multiplexed Fluorescent Microsphere Immunoassay ◽  
Microsphere Immunoassay

ABSTRACT Antibodies to extractable nuclear antigens (ENA) are found in a variety of collagen vascular diseases. Determining the individual specificities of these antibodies is extremely useful in establishing the disease diagnosis and in some cases the prognosis. With a multiplexed fluorescent microsphere immunoassay, reactivity to five of the most diagnostically useful ENA was measured in 249 serum samples, including samples from 56 patients previously documented to have systemic lupus erythematosus (SLE). Results of the multiplexed assay were compared to results from established ENA enzyme-linked immunosorbent assays (ELISAs), and the agreement, sensitivity, and specificity, respectively, for the five ENA evaluated were as follows: SSA, 99.1, 100.0, and 98.8%; SSB, 98.6, 88.9, and 99.5%; Sm, 97.6, 95.8, and 97.9%; RNP, 97.2, 92.7, and 98.8%; Scl-70, 93.6, 50.0, and 99.0%. In the 56 confirmed SLE patients, the frequency of significant concentrations of autoantibodies with the multiplexed assay was 21.4% for SSA, 7.1% for SSB, 10.7% for Sm, 32.1% for RNP, and 0% for Scl-70. The new flow cytometric bead-based multiplexed assay showed excellent correlation with the well-established single-analyte ELISA methods for four of five the ENA markers investigated in this study. The most notable discrepancies between the two assays were for the Scl-70 antigen, which was most often resolved in favor of the multiplexed assay. Our studies show that the multiplexed microsphere-based immunoassay is a sensitive and specific method for the detection and semiquantitation of ENA antibodies in human sera.

scholarly journals Determination of Cytokine Responses Using a Multiplexed Fluorescent Microsphere Immunoassay

2002 ◽  
Vol 118 (3) ◽  
pp. 346-353 ◽  
Author(s):  
Thomas B. Martins ◽  
Brian M. Pasi ◽  
Jerry W. Pickering ◽  
Troy D. Jaskowski ◽  
Christine M. Litwin ◽  
...  
Keyword(s):  
Fluorescent Microsphere ◽  
Cytokine Responses ◽  
Multiplexed Fluorescent Microsphere Immunoassay ◽  
Microsphere Immunoassay

scholarly journals A Multiplexed Fluorescent Microsphere Immunoassay for Antibodies to Pneumococcal Capsular Polysaccharides

2002 ◽  
Vol 117 (4) ◽  
pp. 589-596 ◽  
Author(s):  
Jerry W. Pickering ◽  
Thomas B. Martins ◽  
Ryan W. Greer ◽  
M. Carl Schroder ◽  
Mark E. Astill ◽  
...  
Keyword(s):  
Capsular Polysaccharides ◽  
Fluorescent Microsphere ◽  
Multiplexed Fluorescent Microsphere Immunoassay ◽  
Microsphere Immunoassay

scholarly journals Heterophile Antibody Interference in a Multiplexed Fluorescent Microsphere Immunoassay for Quantitation of Cytokines in Human Serum

2004 ◽  
Vol 11 (2) ◽  
pp. 325-329 ◽  
Author(s):  
Thomas B. Martins ◽  
Brian M. Pasi ◽  
Christine M. Litwin ◽  
Harry R. Hill
Keyword(s):  
Human Serum ◽  
Biological Fluids ◽  
Internal Controls ◽  
Fluorescent Microsphere ◽  
Simultaneous Quantification ◽  
And Control ◽  
Multiplexed Fluorescent Microsphere Immunoassay ◽  
Microsphere Immunoassay ◽  
Assay Interference

ABSTRACT While modern immunoassays provide sensitive and specific means for the quantitation of cytokines in biological fluids, heterophile antibodies are still a well-recognized cause of interference in the measurement of cytokines in these assays. We have developed a multiplexed fluorescent microsphere immunoassay for the simultaneous quantification of 10 cytokines in only 75 μl of serum. During the development of this multiplexed assay, the amount of assay interference due to heterophile antibodies was also determined, and methods for detecting heterophile interference and minimizing its effect were incorporated into the assay. Heterophile antibodies resulted in significantly elevated cytokine values compared to those of normal blood bank samples. These falsely elevated values, and thus the components of the assay the heterophile antibodies were binding to, were identified through the use of internal controls. This information was then used to design assay-specific blockers and absorbents that were shown to significantly reduce falsely elevated cytokine values while not affecting the standard and control values. The fluorescent multiplexed microsphere-based immunoassay can be used to quantitate multiple cytokines from a single sample and should be a useful tool in furthering our understanding of the role of cytokines in disease processes.

scholarly journals Fabry Cardiomyopathy: Current Practice and Future Directions

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1532
Author(s):  
Jeffrey Yim ◽  
Olivia Yau ◽  
Darwin F. Yeung ◽  
Teresa S. M. Tsang
Keyword(s):  
Fabry Disease ◽  
Early Stage ◽  
Point Of Care ◽  
Left Ventricular ◽  
The Body ◽  
Cardiac Biomarkers ◽  
Dried Blood Spot ◽  
Point Of Care Ultrasound ◽  
Enzyme Replacement ◽  
Blood Spot

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the galactosidase A (GLA) gene that result in deficient galactosidase A enzyme and subsequent accumulation of glycosphingolipids throughout the body. The result is a multi-system disorder characterized by cutaneous, corneal, cardiac, renal, and neurological manifestations. Increased left ventricular wall thickness represents the predominant cardiac manifestation of FD. As the disease progresses, patients may develop arrhythmias, advanced conduction abnormalities, and heart failure. Cardiac biomarkers, point-of-care dried blood spot testing, and advanced imaging modalities including echocardiography with strain imaging and magnetic resonance imaging (MRI) with T1 mapping now allow us to detect Fabry cardiomyopathy much more effectively than in the past. While enzyme replacement therapy (ERT) has been the mainstay of treatment, several promising therapies are now in development, making early diagnosis of FD even more crucial. Ongoing initiatives involving artificial intelligence (AI)-empowered interpretation of echocardiographic images, point-of-care dried blood spot testing in the echocardiography laboratory, and widespread dissemination of point-of-care ultrasound devices to community practices to promote screening may lead to more timely diagnosis of FD. Fabry disease should no longer be considered a rare, untreatable disease, but one that can be effectively identified and treated at an early stage before the development of irreversible end-organ damage.

Sign in / Sign up

Export Citation Format

Share Document